Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
97
-
Total 13F shares, excl. options
-
52.8M
-
Shares change
-
+7.84M
-
Total reported value, excl. options
-
$571M
-
Value change
-
+$86.5M
-
Put/Call ratio
-
1
-
Number of buys
-
57
-
Number of sells
-
-41
-
Price
-
$10.85
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q4 2020
115 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q4 2020.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 97 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 52.8M shares
.
Largest 10 shareholders include ARK Investment Management LLC (9.04M shares), FMR LLC (6.64M shares), Bain Capital Life Sciences Investors, LLC (5.79M shares), Sumitomo Mitsui Trust Holdings, Inc. (4.38M shares), Nikko Asset Management Americas, Inc. (4.38M shares), BlackRock Inc. (3.33M shares), Ally Bridge Group (NY) LLC (2.64M shares), Samsara BioCapital, LLC (2.19M shares), VANGUARD GROUP INC (2.04M shares), and ORBIMED ADVISORS LLC (1.56M shares).
This table shows the top 97 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.